Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials
Kristina Bryant, Jodie McVernon, Colin Marchant, Terry Nolan, Gary Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen Lambert, Emmanuel Aris, Narcisa Mesaros, Jacqueline Miller, Kristina Bryant, Jodie McVernon, Colin Marchant, Terry Nolan, Gary Marshall, Peter Richmond, Helen Marshall, Michael Nissen, Stephen Lambert, Emmanuel Aris, Narcisa Mesaros, Jacqueline Miller
Abstract
A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjugated to N. meningitidis outer membrane protein) coadministered with measles-mumps-rubella (MMR) and varicella (VAR) vaccines (NCT00134719/NCT00289783). Noninferiority of immunological responses to MMR and VAR was demonstrated between groups and incidences of MMR- and VAR-specific solicited symptoms were similar, indicating that HibMenCY-TT can be coadministered with MMR and VAR.
Figures
References
- Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25:8487–99. doi: 10.1016/j.vaccine.2007.10.013.
- Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age. Hum Vaccin. 2010;6:640–51. doi: 10.4161/hv.6.8.12154.
- Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, et al. HibMenCY-TT 005 Study Group Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2010;29:48–52. doi: 10.1097/INF.0b013e3181c3ce88.
- Nolan T, Richmond P, Marshall H, McVernon J, Alexander K, Mesaros N, et al. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2011;30:190–6. doi: 10.1097/INF.0b013e3181fcb2bf.
- Bryant KA, Marshall GS, Marchant CD, Pavia-Ruiz N, Nolan T, Rinderknecht S, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics. 2011;127:e1375–85. doi: 10.1542/peds.2009-2992.
- Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau D, Poolman JT, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr Infect Dis J. 2010;29:469–71. doi: 10.1097/INF.0b013e3181cdd379.
- Advisory Committee on Immunization Practices. 2011 Child & Adolescent Immunization Schedules. Accessed July 03, 2011.
- ActHIB [package insert]. Swiftwater, PA: Sanofi Pasteur Inc.; 2009.
- Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, et al. Consistency Lot Study Group for ProQuad The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006;25:615–22. doi: 10.1097/01.inf.0000220209.35074.0b.
- Wellington K, Goa KL. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs. 2003;63:2107–26. doi: 10.2165/00003495-200363190-00012.
Source: PubMed